1194 related articles for article (PubMed ID: 22314934)
41. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
42. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
43. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.
Liu YM; Xia Y; Dai W; Han HY; Dong YX; Cai J; Zeng X; Luo FY; Yang T; Li YZ; Chen J; Guan J
BMC Cancer; 2014 Nov; 14():889. PubMed ID: 25429777
[TBL] [Abstract][Full Text] [Related]
44. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
Zhao X; Li J; Zhuo J; Cai L
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
[TBL] [Abstract][Full Text] [Related]
45. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.
Chen G; Wang Y; Zhou M; Shi H; Yu Z; Zhu Y; Yu F
Oncol Rep; 2010 Feb; 23(2):563-70. PubMed ID: 20043122
[TBL] [Abstract][Full Text] [Related]
46. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
[TBL] [Abstract][Full Text] [Related]
47. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
48. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
49. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
50. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX; Sahani DV; Duda DG; di Tomaso E; Ancukiewicz M; Catalano OA; Sindhwani V; Blaszkowsky LS; Yoon SS; Lahdenranta J; Bhargava P; Meyerhardt J; Clark JW; Kwak EL; Hezel AF; Miksad R; Abrams TA; Enzinger PC; Fuchs CS; Ryan DP; Jain RK
J Clin Oncol; 2009 Jun; 27(18):3027-35. PubMed ID: 19470923
[TBL] [Abstract][Full Text] [Related]
51. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
52. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
53. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
54. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
55. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
56. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
57. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
58. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
[TBL] [Abstract][Full Text] [Related]
59. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.
Bagi CM; Christensen J; Cohen DP; Roberts WG; Wilkie D; Swanson T; Tuthill T; Andresen CJ
Cancer Biol Ther; 2009 May; 8(9):856-65. PubMed ID: 19458500
[TBL] [Abstract][Full Text] [Related]
60. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Avella DM; Li G; Schell TD; Liu D; Zhang SS; Lou X; Berg A; Kimchi ET; Tagaram HR; Yang Q; Shereef S; Garcia LS; Kester M; Isom HC; Rountree CB; Staveley-O'Carroll KF
Hepatology; 2012 Jan; 55(1):141-52. PubMed ID: 21898502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
